Bio-Connect

Mouse anti Human CD13, conjugated with FITC

Research Use Only
0132
Nordic-MUbio
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetANPEP
Price on request
100 tests
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Nordic-MUbio
  • Product Name
    Mouse anti Human CD13, conjugated with FITC
  • Delivery Days Customer
    7
  • Application Supplier Note
    PBMC: Add10 microl of MAB/10^6 PBMC in 100 microl PBS. Mix gently and incubate for 15 minutes at 2 to 8C. Wash twice with PBS and analyze. WHOLE BLOOD: Add 10 microl of MAB/100 microl of whole blood. Mix gently and incubate for 15 minutes at room temperature (20C). Lyse the whole blood. Wash once with PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
  • Applications
    Flow Cytometry
  • Applications Supplier
    Flow Cytometry
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    E735
  • Conjugate
    FITC
  • Gene ID290
  • Target name
    ANPEP
  • Target description
    alanyl aminopeptidase, membrane
  • Target synonyms
    alanyl (membrane) aminopeptidase; aminopeptidase M; aminopeptidase N; AP-M; APN; AP-N; CD13; GP150; hAPN; LAP1; membrane alanyl aminopeptidase; microsomal aminopeptidase; myeloid plasma membrane glycoprotein CD13; P150; PEPN
  • Host
    Mouse
  • Isotype
    IgG1
  • Protein IDP15144
  • Protein Name
    Aminopeptidase N
  • Scientific Description
    CD13 FITC
  • Shelf life instruction
    See expiration date on vial
  • Reactivity
    Human
  • Reactivity Supplier
    Human
  • Reactivity Supplier Note
    CD13=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c x C57BL16 hybrid mice immunized with KG-1a cell line.
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • 1. Induction of CD13 expression on fresh myeloid leukemia: correlation of CD13 expression with aminopeptidase-N activity. Razak K; Newland AC Leuk Res 1992 Jun-Jul;16(6-7):625-30. 2. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4. 3. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A Cancer 1992 Jan 15;69(2):396-404. 4. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T Acta Haematol 1992;87(1-2):88-93.